Search for Doubly-Charged Higgs Boson Production at HERA

A search for the single production of doubly-charged Higgs bosons H^{\pm \pm} in ep collisions is presented. The signal is searched for via the Higgs decays into a high mass pair of same charge leptons, one of them being an electron. The analysis uses up to 118 pb^{-1} of ep data collected by the H1 experiment at HERA. No evidence for doubly-charged Higgs production is observed and mass dependent upper limits are derived on the Yukawa couplings h_{el} of the Higgs boson to an electron-lepton pair. Assuming that the doubly-charged Higgs only decays into an electron and a muon via a coupling of electromagnetic strength h_{e \mu} = \sqrt{4 \pi \alpha_{em}} = 0.3, a lower limit of 141 GeV on the H^{\pm\pm} mass is obtained at the 95% confidence level. For a doubly-charged Higgs decaying only into an electron and a tau and a coupling h_{e\tau} = 0.3, masses below 112 GeV are ruled out.Comment: 15 pages, 3 figures, 1 tabl

Première mesure des sections efficaces de courant chargé et neutre avec le faisceau de positrons polarisé à HERA II et analyses QCD-électrofaibles

In 2003--2004 the HERA collider delivered $e^+p$ collisions with a longitudinally polarised positron beam. We present the measurement of inclusive Neutral and Charged Current DIS cross section using the H1 detector. The total Charged Current cross section for $Q^2>400$ GeV$^2$, $y400$ GeV$^2$, $y<0,9$ donne \begin(eqnarray \sigma_(CC)(P=+0,33)&=& 34,67\mbox( pb )\pm 1,94\mbox( pb )\:(\mbox(stat))\pm 1,66\mbox( pb )\:(\mbox(sys)) \\ \sigma_(CC)(P=-0,40)&=& 13,80\mbox( pb )\pm 1,04\mbox( pb )\:(\mbox(stat))\pm 0,94\mbox( pb )\:(\mbox(sys)). \end(eqnarray) En accord avec le Modèle Standard qui prédit la proportionnalité de la section efficace avec la polarisation. Dans une deuxième partie, on réalise une analyse QCD des données de H1 pour extraire les densités de partons. Cette analyse est ensuite étendue à la détermination jointe des paramètres électrofaibles comme la masse du boson $W$ et des couplages des quarks au boson $Z$. Une analyse QCD globale des données de DIS et de Drell-Yan est réalisée, en particulier utilisée pour obtenir l'asymétrie de la mer étrange $\int_0^1 x(s-\bar(s))\mathrm(d)x=(1,8\pm3,8)\times10^(-4)$. L'impact des nouvelles données de E866 sur les densités de quark à très grand $x$ est discuté. On obtient une extraction de la constante de couplage forte \alpha_s=0,1197\pm0,0008 \mbox( (exp)) ()^(+0,0005)_(-0,0007)\mbox( (mod))\pm0,006 \mbox( (th))

H1 QCD analysis of inclusive cross section data

This contribution reviews the QCD analysis of the H1 inclusive DIS data. Flavor separated parton densities are extracted in a NLO QCD fit using neutral and charged current HERA I data. The results of a dedicated QCD analysis of the gluon and $\alpha_s$ are also reviewed

High Q**2 Structure Functions and Parton Distributions

This contribution reviews the main achievements in inclusive measurements made by the H1 and ZEUS collaborations during the first phase of HERA data taking. The QCD analysis of these data by both collaborations are described. The case for a common QCD analysis is briefly discussed, with an emphasis on the possible $W$ mass extraction

High Q2\mathrm{Q^2} structure functions and parton distributions

This contribution reviews the main achievements in inclusive measurements made by the H1 and ZEUS collaborations during the first phase of HERA data taking. The QCD analysis of these data by both collaborations are described. The case for a common QCD analysis is briefly discussed, with an emphasis on the possible $W$ mass extraction

Parton distribution functions in a fit of DIS and related data

Groupe H1We present a NLO analysis of DIS and related data, including high-statistics $\nu, \bar{\nu}$ cross section measurements. The parton distributions functions of the proton are extracted. A detailed study of the strange and antistrange densities is performed, and the charge symmetry of the strange sea is tested. We discuss the impact of the results on the NuTeV $sin^2 \theta_w$ puzzle

Specific gut microbial, biological, and psychiatric profiling related to binge eating disorders: A cross-sectional study in obese patients.

BACKGROUND & AIMS: Binge eating disorder (BED) is a frequent eating disorder associated with obesity and co-morbidities including psychiatric pathologies, which represent a big health burden on the society. The biological processes related to BED remain unknown. Based on psychological testing, anthropometry, clinical biology, gut microbiota analysis and metabolomic assessment, we aimed to examine the complex biological and psychiatric profile of obese patients with and without BED. METHODS: Psychological and biological characteristics (anthropometry, plasma biology, gut microbiota, blood pressure) of 101 obese subjects from the Food4Gut cohort were analysed to decipher the differences between BED and Non BED patients, classified based on the Questionnaire for Eating Disorder Diagnosis (Q-EDD). Microbial 16S rDNA sequencing and plasma non-targeted metabolomics (liquid chromatography-mass spectrometry) were performed in a subcohort of 91 and 39 patients respectively. RESULTS: BED subjects exhibited an impaired affect balance, deficits in inhibition and self-regulation together with marked alterations of eating behaviour (increased emotional and external eating). BED subjects displayed a lower blood pressure and hip circumference. A decrease in Akkermansia and Intestimonas as well as an increase in Bifidobacterium and Anaerostipes characterized BED subjects. Interestingly, metabolomics analysis revealed that BED subjects displayed a higher level of one food contaminants, Bisphenol A bis(2,3-dihydroxypropyl) ether (BADGE.2H(2)O) and a food derived-metabolite the Isovalerylcarnitine. CONCLUSIONS: Non-targeted omics approaches allow to select specific microbial genera and two plasma metabolites that characterize BED obese patients. Further studies are needed to confirm their potential role as drivers or biomarkers of binge eating disorder. Food4gut, clinicaltrial.gov:NCT03852069, https://clinicaltrials.gov/ct2/show/NCT03852069

Link between gut microbiota and health outcomes in inulin -treated obese patients: Lessons from the Food4Gut multicenter randomized placebo-controlled trial.

peer reviewedBACKGROUND: The gut microbiota is altered in obesity and is strongly influenced by nutrients and xenobiotics. We have tested the impact of native inulin as prebiotic present in vegetables and added as a supplement on gut microbiota-related outcomes in obese patients. Metformin treatment was analyzed as a potential modulator of the response. METHODS: A randomized, single-blinded, multicentric, placebo-controlled trial was conducted in 150 obese patients who received 16 g/d native inulin versus maltodextrin, coupled to dietary advice to consume inulin-rich versus -poor vegetables for 3 months, respectively, in addition to dietary caloric restriction. Anthropometry, diagnostic imaging (abdominal CT-scan, fibroscan), food-behavior questionnaires, serum biology and fecal microbiome (primary outcome; 16S rDNA sequencing) were analyzed before and after the intervention. RESULTS: Both placebo and prebiotic interventions lowered energy intake, BMI, systolic blood pressure, and serum γ-GT. The prebiotic induced greater weight loss and additionally decreased diastolic blood pressure, AST and insulinemia. Metformin treatment compromised most of the gut microbiota changes and metabolic improvements linked to prebiotic intervention. The prebiotic modulated specific bacteria, associated with the improvement of anthropometry (i.e. a decrease in Desulfovibrio and Clostridium sensu stricto). A large increase in Bifidobacterium appears as a signature of inulin intake rather than a driver of prebiotic-linked biological outcomes. CONCLUSIONS: Inulin-enriched diet is able to promote weight loss in obese patients, the treatment efficiency being related to gut microbiota characteristics. This treatment is more efficacious in patients who did not receive metformin as anti-diabetic drugs prior the intervention, supporting that both drug treatment and microbiota might be taken into account in personalized nutrition interventions. Registered under ClinicalTrials.gov Identifier no NCT03852069